НЬИВЕНХЕЙЗЕН Виллем Фердинанд (NL),БЕН АМОР Каоутер (NL),КНОЛ Ян (NL),ВАН ДЕР БЕК Элине Марлен (NL),БЕЕРМАНН Кристофер (DE),СПЕЛМАНС Гелске (NL)
申请号：
RU2012155333/13
公开号：
RU2012155333A
申请日:
2012.12.19
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
1. The use of a food composition containing: A. a sphingophospholipid, preferably sphingomyelin and / or at least one sphingophospholipid degradation product selected from the group consisting of ceramide, lysophosphophospholipid, sphingoid phosphate and free sphingoid base, and B. at least fructooligosaccharides and galactooligosaccharides, for the production of a composition for normalizing intestinal microbiota in humans to microbiota in healthy slender subjects and / or breast-fed children, where the composition of the intestinal microbiota is normalized with respect to at least one characteristic selected from a decrease in the Firmicutes / Bacteroidetes ratio , reducing the ratio of Clostridia / Bacteroidetes and reducing the ratio of Enterobacteia / total bacteria. 2. The use according to claim 1, in which the age of the specified person is less than 36 months. The use according to claim 2, in which the microbiota remains normalized when the specified person reaches the age of more than 36 months. The use according to any one of claims 1 to 3 for the prevention of obesity and / or obesity, more preferably in a person under the age of 36 months, and for the prevention of obesity and / or obesity when said person has reached the age of more than 36 months. The use according to claim 4 for the prevention of disorders selected from the group consisting of type 2 diabetes, fasting hyperglycemia, insulin resistance, visceral obesity, hyperinsulinemia, hypertension, cardiovascular disease, cerebrovascular disease, arthrosclerosis, dyslipidemia, hyperuricemia, liver obesity, osteoarthritis sleep apnea. 6. The use according to any one of claims 1 to 3 for the treatment and / or prevention of gastric1. Применение пищевой композиции, содержащей:А. сфингофосфолипид, предпочтительно сфингомиелин и/или по меньшей мере один продукт деградации сфингофосфолипида, выбранный из группы, состоящей из церамида, лизосфингофосфолипида, сфингоидного фосфата и свободного сфингоидного
